| Literature DB >> 22377426 |
Margo E Chase-Topping1, Tracy Rosser, Lesley J Allison, Emily Courcier, Judith Evans, Iain J McKendrick, Michael C Pearce, Ian Handel, Alfredo Caprioli, Helge Karch, Mary F Hanson, Kevin G J Pollock, Mary E Locking, Mark E J Woolhouse, Louise Matthews, J Chris Low, David L Gally.
Abstract
Escherichia coli O26 and O157 have similar overall prevalences in cattle in Scotland, but in humans, Shiga toxin-producing E. coli O26 infections are fewer and clinically less severe than E. coli O157 infections. To investigate this discrepancy, we genotyped E. coli O26 isolates from cattle and humans in Scotland and continental Europe. The genetic background of some strains from Scotland was closely related to that of strains causing severe infections in Europe. Nonmetric multidimensional scaling found an association between hemolytic uremic syndrome (HUS) and multilocus sequence type 21 strains and confirmed the role of stx(2) in severe human disease. Although the prevalences of E. coli O26 and O157 on cattle farms in Scotland are equivalent, prevalence of more virulent strains is low, reducing human infection risk. However, new data on E. coli O26-associated HUS in humans highlight the need for surveillance of non-O157 enterohemorrhagic E. coli and for understanding stx(2) phage acquisition.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22377426 PMCID: PMC3309639 DOI: 10.3201/eid1803.111236
Source DB: PubMed Journal: Emerg Infect Dis ISSN: 1080-6040 Impact factor: 6.883
Source of Escherichia coli O26 isolates and sample sizes for the various statistical analyses, Scotland*
| Source | Country of origin | Analyses | No. isolates | Clinical information |
|---|---|---|---|---|
| Bovine† | Scotland | Prevalence | 249 | NR |
| Bovine† | Scotland | PFGE | 154 | NR |
| Bovine† | Scotland | MLST | 33 | NR |
| Human‡ | Scotland | PFGE | 12 | NK |
| Human‡ | Scotland | MLST | 11 | D (n = 8); BD (n = 2); NK (n = 1) |
| Human§ | England | PFGE | 4 | NK |
| Human§ | Ireland | PFGE | 11 | NK |
| Human§ | Belgium | PFGE | 2 | NK |
| Human§ | Sweden | PFGE | 3 | NK |
| Human§ | Italy | PFGE | 1 | NK |
| Human¶ | Italy | MLST | 5 | HC (n = 1); HUS (n = 4) |
| Human# | Germany | MLST | 14 | D (n = 6); HUS (n = 8) |
*NR, not relevant; PFGE, pulsed-field gel electrophoresis; MLST, multilocus sequence typing; NK, not known; D, diarrhea; BD, bloody diarrhea, HC, hemorragic colitis; HUS, hemolytic uremic syndrome. Where appropriate, the number of isolates from each clinical designation is provided. †Isolated 2002–2004 (). ‡L.J. Allison, Scottish E. coli O157/VTEC Reference Laboratory, Edinburgh, UK; isolated 2002–2003. §H. Smith, Laboratory of Gastrointestinal Pathogens, Colindale, UK. The years isolated are unknown. ¶A. Caprioli, Instituto Superiore di Sanità, Rome, Italy. The years isolated are unknown. #H. Karch, University of Műnster, Műnster, Germany; isolated 1994–2000.
Primers and PCR conditions for Escherichia coli O26, Scotland
| Primer name | Primer sequence, 5′ → 3′ | Target gene | Annealing | Amplicon size, bp | Reference |
|---|---|---|---|---|---|
| stx1F stx1R | ATAAATCGCCATTCGTTGACTAC AGAACGCCCACTGAGATCATC |
| 60°C,45 s | 180 | ( |
| stx2F stx2R | GGCACTGTCTGAAACTGCTCC TCGCCAGTTATCTGACATTCTG |
| 60°C,45 s | 255 | ( |
| eaeAF eaeAR | GACCCGGCACAAGCATAAGC CCACCTGCAGCAACAAGAGG |
| 60°C,45 s | 384 | ( |
| hlyAF hlyAR | GCATCATCAAGCGTACGTTCC AATGAGCCAAGCTGGTTAAGCT |
| 60°C,45 s | 534 | ( |
| sepLF sepLR | GCTAAGCCTGGGATATCGC ACAATCGATACCCGAGAAGG |
| 60°C,45 s | 725 | This study |
| univ tccP/tccp2-F tccP-R | GTAAAAACCAGCTCACCTTTTTC TCACGAGCGCTTAGATGTATTAAT | 64°C,60 s | Variable | ( | |
| espAF espAR | CCTTCTCGGGTATCGATTGTCG CAGAGGGCGTCACTAATGAGTG |
| 58°C,60 s | 1012 | This study |
| LEE1promF LEE1promR | CGAATGGTACGGTTATGCGGG GCTCTCGCAGTCGCTTTGCTTCC |
| 58°C,60 s | 645 | This study |
Figure 1Isolates of Escherichia coli O26 (A; n = 249) and O157 (B; n = 507), collected from a 2002–2004 field survey, that illustrate the differences between the 2 serogroups from Scotland with reference to the presence or absence of Shiga toxin gene (stx and stx) and the eae gene.
Figure 2Location of farms sampled in 2002–2004 field survey for Escherichia coli O26, Scotland. A) Farms that were positive for E. coli O26 are shown in red; farms negative for E. coli O26 are shown in green. B) The positive farms were subdivided according to differences in virulent properties of E. coli O26 (farm status) based on the possession of stx. Farms were designated as stx– (blue), stx+ (yellow), or stx+stx+ (red).
Farm-level and fecal pat–level prevalence of Escherichia coli O26, Scotland*
| Farms, n = 338 | Fecal pats, n = 6,086 | ||||||
|---|---|---|---|---|---|---|---|
| No. positive | Observed prevalence | Adjusted prevalence (95% CI) | No. positive | Observed prevalence | Adjusted prevalence (95% CI) | ||
| 68 | 0.20 | 0.22 (0.18–0.27) | 249 | 0.041 | 0.046 (0.031–0.062) | ||
| 38 | 0.11 | 0.12 (0.09–0.16) | 122 | 0.020 | 0.020 (0.012–0.029) | ||
| 13 | 0.04 | 0.06 (0.031–0.09) | 97 | 0.016 | 0.004 (0.001–0.008) | ||
| 12 | 0.04 | 0.05 (0.03–0.09) | 24 | 0.004 | 0.004 (0.001–0.007) | ||
*Minor differences in the farm-level prevalence estimates for E. coli O26 between Pearce et al. () and this study resulted from use of different statistical models. Pearce et al. () aimed to provide national prevalence estimates; thus, weighted estimates of mean prevalence were generated that accounted for the fractions of the national herd found in different Animal Health Districts (AHDs). By contrast, we reported the mean of the sample collected in a stratified fashion across the AHDs. Because there were only relatively small differences in mean prevalence in the different AHDs, the effect on the 2 means is negligible and the effect on the standard errors relatively small.
Results of genotypic characterization by MLST and the presence of virulence genes for Escherichia coli O26 isolates, Scotland*
| Genotypic characterization | No. (%) Isolates from humans, n = 30 | No. (%) isolates from cattle, Scotland, n = 33 | |
|---|---|---|---|
| Scotland | Germany/Italy | ||
| MLST | |||
| ST | |||
| 21 | 4 (36.4) | 14 (73.7) | 22 (66.6) |
| 29 | 4 (36.4) | 5 (26.3) | 9 (27.3) |
| Other | 3 (27.2) | 0 | 2 (6.1) |
| ST complex† | |||
| 29 | 10 (90.9) | 19 (100.0) | 31 (93.9) |
| 10 | 1 (9.1) | 0 | 2 (6.1) |
|
| |||
| Allele 1 | 9 (81.8) | 19 (100.0) | 31 (100.0) |
| Other | 1 (9.1) | 0 | 0 |
| ND | 1 (9.1) | 0 | 0 |
| Upstream of | |||
| Allele1 | 2 (18.2) | 14 (73.7) | 7 (21.2) |
| Allele2 | 5 (45.4) | 5 (26.3) | 20 (60.6) |
| allele3 | 0 | 0 | 1 (3.0) |
| allele4 | 1 (9.1) | 0 | 3 (9.1) |
| allele5 | 1 (9.1) | 0 | 0 |
| allele6 | 1 (9.1) | 0 | 0 |
| ND | 1 (9.1) | 0 | 2 (6.1) |
| Presence of virulence genes | |||
|
| |||
|
| 6 (54.5) | 4 (21.1) | 7 (21.2) |
|
| 3 (27.3) | 5 (26.3) | 16 (48.5) |
|
| 2 (18.2) | 10 (52.6) | 10 (30.3) |
|
| |||
| Absent | 1 (9.1) | 0 | 2 (6.1) |
| Present | 10 (90.9) | 19 (100.0) | 31 (93.9) |
|
| |||
| Absent | 1 (9.1) | 0 | 2 (6.1) |
| Present | 10 (90.9) | 19 (100.0) | 31 (93.9) |
|
| |||
| Absent | 3 (27.3) | 7 (36.8) | 6 (18.2) |
| Present | 8 (72.7) | 12 (63.2) | 27 (81.8) |
|
| |||
| Absent | 11 (100.0) | 19 (100.0) | 33 (100.0) |
| Present | 0 | 0 | 0 |
|
| |||
| Absent | 6 (54.5) | 2 (10.5) | 16 (48.5) |
| Present | 5 (45.5) | 17 (89.5) | 17 (51.5) |
*MLST, multilocus sequence typing; ST, sequence type; ND, not determined; stx, Shiga toxin; +, stx gene present; –, stx gene absent. LEE1 encodes the first operon of the locus of enterocyte effacement (LEE) and the 644-bp region sequenced includes the promoter for this operon amplified using the defined LEE primer pair in Table 2. †The ST and ST complex were assigned in accordance with the E. coli MLST database (http://mlst.ucc.ie/mlst/dbs/Ecoli). ‡espA encodes for the surface-associated protein, espA. The allele numbers at each loci were assigned in the order in which they were discovered. §Six different sequences were discovered for the region upstream of LEE1 in the E. coli O26 isolates. Approximately 644 bp of sequence data were determined, and all sequence variation between the E. coli O26 alleles occurs within a 91-bp region upstream of LEE1 in the region where regulators act in E. coli O157:H7. The allele numbers at each locus were assigned in the order in which they were discovered. ¶eae, gene that encodes intimin. #sepL, gene confirming the presence of LEE pathogenicity island. **hlyA, enterohemolysin. ††tccP/tccP2, genes encoding Tir-cytoskeleton coupling protein and Tir-cytoskeleton coupling protein 2, which are used in actin polymerization and subsequent attaching and effacing lesion formation.
Figure 3Patterns in data associated with the clinical severity of Escherichia coli O26 infection in humans, as identified by nonmetric multidimensional scaling, Scotland. A) Joint graph illustrating the association between the multilocus sequence typing and genotypic variables measured and the severity of the human infection (hemolytic uremic syndrome [HUS] in red and non-HUS [diarrhea, bloody diarrhea] in green). B) 3-dimensional scatterplot and 80% confidence ellipses (R rgl package []) around the cases in space illustrating the separation between individual classes as HUS (green) and non-HUS (red).
Figure 4Schematic comparing farm-level (A) and animal-level (B) prevalences of Escherichia coli O157 and E. coli O26 in Scotland for different virulence levels. Analysis was done by using only the 338 farms sampled for both E. coli O157 and E. coli O26.
Figure 5Escherichia coli O157 and Shiga toxin–producing non-O157 E. coli infection in humans in Scotland identified or confirmed by the Scottish E. coli O157/VTEC Reference Laboratory, Edinburgh, UK, by financial year (April–March). Samples include isolates, feces, and serum. Non-O157 isolates were serotyped by the Laboratory of Gastrointestinal Pathogens. Data are presented as percentage of all cases in humans that are E. coli O157 (blue), Shiga toxin-producing non-O157 (excluding E. coli O26) (yellow) and Shiga toxin–producing E. coli O26 (pink). The mean number of cases per financial year during 2006–2011 was 248 (221–275). This time frame was selected to ensure application of consistent method.